At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
0.2g once, 3 times a day,two weeks
Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
Department and Institute of Infectious Disease
Wuhan, Hubei, China
RECRUITINGRate of disease remission
A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2\> 93% or PaO2/FiO2\> 300mmHg (1mmHg=0.133Kpa);
Time frame: two weeks
Time for lung recovery
Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.
Time frame: two weeks
Rate of no fever
Time frame: two weeks
Rate of respiratory symptom remission
Time frame: two weeks
Rate of lung imaging recovery
Time frame: two weeks
Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery
Time frame: two weeks
Rate of undetectable viral RNA
Time frame: two weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.